Updated July 2026 · 11 min read

Vasopressor Titration Guide ICU Nurses 2026

Part of the ICU Pharmacology Hub — browse every related guide in one place.

Medical Disclaimer: This article is general educational information for licensed clinicians and students. Vasopressor management requires physician or APRN orders and close clinical monitoring. Always follow your institution's protocols.

Vasopressors are the pharmacological backbone of hemodynamic support in distributive, cardiogenic, and obstructive shock states. ICU nurses adjust these agents in real time based on MAP targets, signs of end-organ perfusion, and evolving hemodynamics. Understanding the mechanism, typical dose range, and clinical behavior of each vasopressor is not optional for bedside ICU nurses — it's the difference between safe and dangerous titration.

The MAP Target — What Are You Aiming For?

For most ICU patients in shock, the default MAP target is 65 mmHg. This threshold is evidence-based (from the SEPSISPAM trial and others) and represents the minimum perfusion pressure needed to maintain renal, cerebral, and mesenteric perfusion in most adults. However, targets must be individualized: chronically hypertensive patients may require MAP 70–80 mmHg to maintain renal perfusion at their autoregulatory baseline; patients with traumatic brain injury often target MAP ≥80 mmHg to maintain cerebral perfusion pressure; patients with cardiogenic shock may tolerate MAP 55–60 mmHg temporarily to reduce afterload. Know your patient's individualized target from the team — don't assume 65 applies to everyone.

Agent 1 — Norepinephrine (Levophed) — First Line

Mechanism: Potent alpha-1 agonist with moderate beta-1 activity. Increases SVR (vasoconstriction) and has modest positive inotropy. Maintains cardiac output better than pure alpha agonists.

Typical dose range: 0.01 to 3 mcg/kg/min. Starting dose typically 0.05 to 0.1 mcg/kg/min and titrate up by 0.05 mcg/kg/min increments every 5 to 15 minutes per protocol.

Clinical behavior: Reliable MAP increase with less tachycardia than dopamine or epinephrine. Peripheral vasoconstriction can impair limb perfusion at high doses (watch for blanching, mottling of extremities). Extravasation causes tissue necrosis — must be administered through a central line. Preferred agent in distributive shock (septic, anaphylactic, neurogenic).

Agent 2 — Vasopressin — Second Line Adjunct

Mechanism: V1 receptor agonist causing direct vasoconstriction, independent of adrenergic receptors. Does not increase heart rate. In high-dose vasopressor states (especially septic shock), endogenous vasopressin is depleted — replacement doses (0.03–0.06 units/min) restore this deficit.

Typical dose: Fixed at 0.03 to 0.04 units/min (not weight-based; not titrated). The primary role is as a norepinephrine-sparing agent — adding vasopressin allows you to reduce norepinephrine dose, which reduces adrenergic side effects. Do not exceed 0.06 units/min without strong justification (higher doses cause digital ischemia, coronary vasospasm, mesenteric ischemia).

Agent 3 — Phenylephrine — Niche Applications

Mechanism: Pure alpha-1 agonist. No beta-1 activity. Increases SVR and MAP but does NOT increase cardiac output — in fact, reflex bradycardia and increased afterload can reduce cardiac output.

When to use: Useful when tachycardia is dangerous (e.g., atrial fibrillation with RVR, HOCM, or aortic stenosis where heart rate control is critical), since phenylephrine's reflex bradycardia is beneficial in these contexts. Avoid in cardiogenic shock (already reduced cardiac output) and vasodilatory shock where maintaining output is critical.

Agent 4 — Epinephrine — Second/Third Line

Mechanism: Potent alpha-1 and beta-1 and beta-2 agonist. Increases MAP, cardiac contractility, heart rate, and cardiac output. Also causes bronchodilation.

Uses in the ICU: Anaphylactic shock (first line, IM/IV), cardiogenic shock requiring both vasopressor and inotropic support, refractory septic shock when norepinephrine + vasopressin are insufficient, post-cardiac arrest to support hemodynamics.

Limitations: Causes significant tachycardia, elevated lactate (via beta-2 stimulation of aerobic glycolysis — a metabolic effect, not necessarily tissue hypoperfusion), increased myocardial oxygen demand, hyperglycemia. Close glucose monitoring is required. A rising lactate in a patient on epinephrine does not automatically mean worsening shock — context and trend matter.

Agent 5 — Dopamine — Generally Avoid in Septic Shock

Dopamine has dose-dependent effects: at low doses, dopaminergic effects predominate; at moderate doses, beta-1 (inotropy/chronotropy); at high doses, alpha-1 (vasoconstriction). The SOAP II trial showed dopamine was associated with more adverse events including arrhythmias compared to norepinephrine in septic shock. Current SSC guidelines recommend against dopamine as a vasopressor in septic shock when norepinephrine is available. Limited use remains: cardiogenic shock (some protocols), bradycardia not responsive to atropine (chronotropic effect).

Vasopressor Weaning Strategy

Wean vasopressors when MAP is consistently at or above target without requiring recent dose increases, fluid status is optimized, and the underlying cause of shock is resolving. Wean the most recently added agent first. Reduce doses in small, conservative decrements (e.g., reduce norepinephrine by 0.02–0.05 mcg/kg/min every 30 to 60 minutes if hemodynamically stable). Monitor MAP, HR, urine output, and clinical signs of perfusion (skin color, cap refill, mental status in awake patients) after each reduction. Vasopressor weaning is not a race — premature weaning and re-escalation is worse than a conservative taper.

Related: ICU sepsis bundle compliance, CRRT vs hemodialysis, arterial line waveform interpretation.